

# Special Issue

## SARS-CoV-2/COVID-19: Infection Models, Therapeutics and Vaccines

### Message from the Guest Editors

Since the end of 2020, new SARS-CoV-2 variants of concern (VOCs) have been emerging worldwide. These variants present new challenges to the control of the COVID-19 pandemic by greatly threatening the efficacies of available monoclonal antibody therapies and vaccines, which have been developed to target the parent strain of SARS-CoV-2. Therefore, continued efforts are required to evaluate the efficacy of currently available and newly developed therapeutics and vaccines against SARS-CoV-2 (including new variants) in relevant infection models to contain and combat this virus efficiently. Therefore, the aim of this Special Issue is to provide a collection of articles that highlight recent advancements in the battle against the SARS-CoV-2 pandemic. As the of this Special Issue, I invite you to submit research articles, review articles, and short communications related to SARS-CoV-2 infection models as well as therapeutics and vaccines development against this virus. Keywords: SARS-CoV-2; animal models; antivirals; vaccine; monoclonal antibodies; assay models

### Guest Editors

Prof. Dr. Johan Neyts

Rega Institute for Medical Research, KU Leuven, Leuven, Belgium

Dr. Rana Abdelnabi

Rega Institute for Medical Research, KU Leuven, Leuven, Belgium

### Deadline for manuscript submissions

closed (15 April 2023)



**Microorganisms**

---

an Open Access Journal  
by MDPI

---

**Impact Factor 4.2**  
**CiteScore 7.7**  
**Indexed in PubMed**



[mdpi.com/si/110415](https://mdpi.com/si/110415)

*Microorganisms*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[microorganisms@mdpi.com](mailto:microorganisms@mdpi.com)

[mdpi.com/journal/  
microorganisms](https://mdpi.com/journal/microorganisms)





## Microorganisms

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.2  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
microorganisms](https://mdpi.com/journal/microorganisms)



## About the Journal

### Message from the Editor-in-Chief

"Microorganism" merges the idea of the very small with the idea of the evolving reproducing organism is a unifying principle for the discipline of microbiology. Our journal recognizes the broadly diverse yet connected nature of microorganisms and provides an advanced publishing forum for original articles from scientists involved in high-quality basic and applied research on any prokaryotic or eukaryotic microorganism, and for research on the ecology, genomics and evolution of microbial communities as well as that exploring cultured microorganisms in the laboratory.

---

### Editor-in-Chief

Dr. Nico Jehmlich

Department of Molecular Toxicology, UFZ-Helmholtz Centre for  
Environmental Research, 04318 Leipzig, Germany

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, AGRIS, and other databases.

#### Journal Rank:

JCR - Q2 (Microbiology) / CiteScore - Q1 (Microbiology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.2 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).